BioCentury
ARTICLE | Top Story

4SC reports OS data for resminostat

September 14, 2012 12:28 AM UTC

4SC AG (Xetra:VSC) reported additional data from the Phase II SHELTER trial showing that second-line treatment with resminostat plus Nexavar sorafenib led to a median overall survival of 8 months in patients with hepatocellular carcinoma refractory to Nexavar. 4SC believes the 8 month median OS in the combination arm is the highest median OS achieved in clinical studies of new therapies for second-line HCC. The result also appears to be an almost three-month improvement over second-line treatment with Nexavar alone. Data from the Phase III SHARP trial of Nexavar showed that median survival after tumor progression was 5.2 months, according to the label for the inhibitor of RAF1 and multiple receptor tyrosine kinases. Bayer AG (Xetra:BAYN) and Onyx Pharmaceuticals Inc. (NASDAQ:ONXX) market Nexavar. ...